Last checked at 
(Correcting that Brindley resigned in July, giving six months notice.)
Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Non-Executive Chair Alastair Riddell will become executive chair from December 1. Back in July, Anne Brindley resigned as chief executive officer, giving six months notice. At the time, Riddell wrote a letter to shareholders to address the "frustration and confusion" that followed the announcement that Brindley was leaving, having only joined Nuformix in December. Riddell had said the departure was "no reflection on Nuformix or her view of the opportunities in the Nuformix pipeline".
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.